Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (April 2022)
17 slides from Bio-gene Technology's investor presentation, April 2022
Slide 1: Bio-Gene Technology Limited Corporate Presentation
BIO-GENE TECHNOLOGY LIMITED (ASX : BGT) ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES April 2022 CORPORATE PRESENTATION PRESENTED BY Richard Jagger Chief Executive Officer & Managing Director
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation
Slide 3: Addressing Significant Global Challenges
Food Security & Public Health Growing Population Current global population is 7.7 billion, growing at 70 million p.a. It is ADDRESSING Challenges Of anticipated that global population will reach nearly 10 billion by 20501. Climbing average temperatures and other weather events impact food SIGNIFICAN
Slide 4: Our Technology Platform
AUSTRALIASIAN AGFOOD CONFERENCE OUR TECHNOLOGY PLATFORM We are developing two products that allow entry into five key market segments QcideTM FlavocideTM Natural Compound Nature Identical Compound Both of our products An extract of a specific cultivar of BGT has developed a proprietary have potentia
Slide 5: Our Proprietary Chemistry Represents a Step-Change for Resistant Pest Control
OUR PROPRIETARY CHEMISTRY REPRESENTS A STEP-CHANGE FOR RESISTANT PEST CONTROL Naturally Derived Chemistry Safe Chemistry Efficacy Novel Mode of Action Qcide is a natural compound and Excellent safety profile based on Testing to date confirms potential Operates via a novel Flavocide is a ‘nature iden
Slide 6: Our Technology Addresses These Challenges and Targets Growing Global Markets
CORPORATE PRESENTATION OUR TECHNOLOGY ADDRESSES THESE CHALLENGES AND TARGETS GROWING GLOBAL MARKETS Bio-Gene’s insecticide platform has potential Crop Protection Food, Fibre & Grain application in large, global market segments Storage 52% estimated to represent a total addressable market Includes gr
Slide 7: Our Strategic Objective
OUR STRATEGIC Generate multiple revenue streams from technology licensing fees, milestone payments and royalties by OBJECTIVE Securing & owning active ingredient product registrations Working with strong commercial partners on product development; marketing and distribution Developing proprietary ma
Slide 8: Significant Positive Progress Across Multiple Fronts
SIGNIFICANT POSITIVE PROGRESS New agreements with commercial partners ACROSS MULTIPLE Development agreements BGT has executed a commercial development agreements with Evergreen Garden Care and Clarke Mosquito Control FRONTS Additional MTAs BGT has entered into new Material Transfer Agreements (MTAs)
Slide 9: Consumer Products: Evergreen Commercial Development Agreement
CONSUMER PRODUCTS: EVERGREEN COMMERCIAL DEVELOPMENT AGREEMENT Evergreen is a market leader in consumer products across Europe and in Australia/New Zealand Market Opportunity Initial Field of Use Initial Territory Revenue Model Fly & mosquito electric evaporator E.U., U.K., A/NZ Up-front licence fee
Slide 10: Public Health: New Commercial Agreement Signed on Clarke Mosquito Project
PUBLIC HEALTH: NEW COMMERCIAL AGREEMENT SIGNED ON CLARKE MOSQUITO PROJECT Clarke is the largest vertically integrated company in public health mosquito control Market Opportunity Initial Field of Use: Results of Phase 2 Testing New Commercial Agreement Next Steps US$100m1 Very positive results indic
Slide 11: Crop Protection: Update on BASF Stored Grain Project
2021 ANNUAL GENERAL MEETING CROP PROTECTION: UPDATE ON BASF STORED GRAIN PROJECT BASF is the world’s largest chemical company Results of Phase 3 show the ability for Results of Phase 3 Testing Flavocide, when used Details of Current Agreement Further Discussions in combination (at low with BASF Fiel
Slide 12: Important Progress Across Other Key Areas
IMPORTANT PROGRESS ACROSS OTHER KEY AREAS I.P. Developments Additional MTAs Efficacy testing • Additional research underway has the potential • Bio-Gene has signed 4 new MTAs in the • Additional studies underway for specific to identify new I.P. for the company past year with international companies
Slide 13: Positive News Flow as We Continue to Execute on the Strategy
POSITIVE NEWS FLOW AS WE CONTINUE TO EXECUTE ON THE STRATEGY 2021& 2022 Announcements have included Mode of Action ü Positive results to confirm novel Mode of Action Efficacy ü Positive efficacy data in the 9 month stored grain pest control study Intellectual Property ü Several new patent allowances
Slide 14: A Clear Road Map for Generating Value
2021 ANNUAL GENERAL MEETING A CLEAR ROAD MAP FOR GENERATING VALUE 2024-2026 – MEDIUM TERM 2022-2024 2021-2022 • First regulatory approval and 2020-2021 • Additional commercial sales application testing - • Additional 2018-2020 • Manufacturing scale- internal and with registration up partners submiss
Slide 15: Funding Position
FUNDING POSITION Sources of future funding: Shares on issue 179,056,519 Market capitalisation $51 million1 Development Government Philanthropic As at March 31, 2022, and commercial grants organisations Cash on hand partnerships focused on public health solutions A$7.2 million Provides working capita
Slide 16: Board Members & Management
BOARD MEMBERS & MANAGEMENT Robert Klupacs Richard Jagger Peter Beetham Chairman CEO & Managing Director Non-Executive Director • 30+ years corporate experience in • 25+ years working in agriculture globally • 30+ years experience in bio-agriculture international tech development • Most recently empl
Slide 17: Bio-Gene Technology Limited Contact
BIO-GENE TECHNOLOGY LIMITED ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES CONTACT RICHARD JAGGER CHIEF EXECUTIVE OFFICER [email protected]
Bio-Gene Technology — Investor Presentation (April 2022) on 6ix